drugset / Trial / NCT00389922
Lapatinib and Vinorelbine in Treating Patients With Advanced Solid Tumors
Phase 1
Completed
22 enrolled
University of California, Davis
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib together with vinorelbine may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib when given together with vinorelbine in treating patients with advanced solid tumors.
Timeline
- Start
- 2005-12
- Primary completion
- 2009-04
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lapatinib | Small molecule | 250 mg | Oral |
| Subject | Lapatinib | Small molecule | 500 mg | Oral |
| Subject | Lapatinib | Small molecule | 1000 mg | Oral |
| Subject | Lapatinib | Small molecule | 1250 mg | Oral |
| Subject | Lapatinib | Small molecule | 1500 mg | Oral |
| Subject | Lapatinib | Small molecule | 1700 mg | Oral |
| Subject | Vinorelbine | Small molecule | 20 mg/m2 | Intravenous |
| Subject | Vinorelbine | Small molecule | 25 mg/m2 | Intravenous |